Abstract
Purpose
To assess the effectiveness of a combination of intense pulsed light and low-level light therapy (IPL/LLLT) for the treatment of dry eye.
Study Design
Retrospective before-after single-center clinical study.
Materials and Methods
Patients diagnosed with dry eye, refractory to conventional treatment, underwent four sessions of combined IPL/LLLT over 3 months. The Ocular Surface Disease Index (OSDI) questionnaire, non-invasive breakup time (NIBUT), tear film osmolarity and meniscus height were measured 6 months before intervention, at baseline, post-intervention (3 months), 9 and 15 months.
Results
NIBUT, osmolarity and meniscus height significantly worsened during the 6 months before treatment, whereas symptoms did not change. OSDI scores significantly improved at post-intervention (MD = −44.0, 95% CI −38.1, −50.0), and then increased again until the at last follow-up, but still significantly different from baseline (MD = −30.0, 95% CI −23.4, −36.8). The three clinical signs showed a similar pattern, with one-year improvements of 3.6 seconds for the NIBUT (95% CI 3.1, 4.2, p <0.001), 28 mOsm/L for osmolarity (95% CI 23.6, 32.4, p <0.001) and 0.03 mm for meniscus height (95% CI 0.02, 0.04, p <0.001). No adverse effects were observed.
Conclusion
IPL/LLLT is safe and produces an important reduction in symptoms and signs of dry eye disease, still relevant one year after the end of treatment in a sample with high symptoms’ severity. Therefore, it represents a promising treatment option for patients who do not improve with conventional treatment. Randomized trials are needed to determine the added benefit provided by LLLT.
Abbreviations
ANOVA, analysis of variance; DED, dry eye disease; IPL, intense pulsed light; LED, light-emitting diodes; LLLT, low-level light therapy; MGD, Meibomian Gland Dysfunction; MD, mean difference; NIBUT, Non-invasive Breakup Time; OSDI, Ocular Surface Disease Index; SPEED, Standardized Patient Evaluation of Eye Dryness; TFOS-DEWS, Tear Film and Ocular Surface Society; TBUT, Tear film Breakup Time.
Acknowledgments
We thank Francisco García, Sílvia Rodriguez and Yurena Rodríguez for their work attending to patients and applying the evaluated treatment.
Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval for the version to be published; have agreed on the journal to which the article has been submitted; and agreed to be accountable for all aspects of the work.
Disclosure
MA Pérez-Silguero declares that Topcon Corporation (Tokyo, Japan), distributor of the Eye-light® device, paid his travel and hotel costs for two national congresses organized by the Spanish Society of Ophthalmology (Granada, 26th-29th September 2018 and Madrid, 25th-28th September 2019), in which he directed two symposiums about dry eye. The remaining authors have no conflicts of interest.